GCF Newsletter : June 2017

Promising Immunotherapy Treatment for Advanced Gastric Cancer

For the first time, the Federal Drug Administration (FDA) has approved a drug for treating all cancers with certain genetic characteristics. Now, patients can try Merck’s Keytruda (pembrolizumab), an immune oncology drug, if they have advanced cancer with pathological microsatellite instability of DNA mismatch repair defects.
This month, the FDA also announced it granted a priority review for Keytruda to treat recurrent or advanced gastric cancer. The FDA agreed to look at the data quickly and provide a decision sooner than the normal 12-month review cycle once all the data are submitted and accepted. Presented at the American Society of Clinical Oncology (ASCO) conference in June, a study found Keytruda is a promising monotherapy for previously treated patients with advanced gastric or gastroesophageal junction cancer, which shows the value of genetically sequencing patients’ tumors. The FDA approval decision is expected this fall. Read more from Cure Today here.
 

New Gastric Research Scholar Shares His Outlook

In May, Jose Saenz, MD, PhD, was named our second Research Scholar with a grant of $90,000 annually for the next three years. This award is a collaboration of our Foundation and the American Gastroenterological Association (AGA).
We asked Dr. Saenz to shed light on his upcoming research at Washington University in St. Louis:
“Infection with the gastric bacterium, Helicobacter pylori is the greatest risk factor for developing gastric cancer. If we can begin to understand how Helicobacter pylori genetically adapts to different regions of the stomach, this may clue us to which bacterial genes are important for survival in these regions, and we can begin to target these genes therapeutically. Then we will be able to detect patients with an increased risk based on the bacterial profiles.”
 

NUTRITION: You’ve Got to Try This

Fresh out of the kitchen! Enjoy this second video in our cooking series with “The Chef with No Stomach,” Board Member, Hans Rueffert. Hans shares his delicious hummus recipe, which is his go-to protein that’s easy to digest. 
Gastric Cancer Foundation is producing this video series in response to the many inquiries we have received regarding the unique nutritional challenges for gastric cancer patients. We welcome your feedback and suggestions as we plan for future episodes.
 

SAVE THE DATE:

Friday, November 17th, 2017
 
 
at the Peninsula Golf & Country Club
San Mateo, California
Please mark your calendar and join us to celebrate progress and raise funds to accelerate the search for better treatments and a cure for gastric cancer. The event will include a special tribute to Wayne Feinstein, who is completing his service as Chairman of the Foundation.
 

Talk it Through

The National Cancer Institute operates a cancer hotline where you can talk to a trained specialist. One can get information about participating in clinical trials and discuss questions to ask doctors. Call 1-800-4-CANCER, go online to chat or email at cancer.gov/contact. Read more about the hotline in the NPR story here.

 

PLEASE SUPPORT OUR WORK

The work of the Gastric Cancer Foundation is made possible through the generosity of caring people who understand the urgency of our cause. Donations provide critical funding for our research initiatives like the Research Scholar Award, the nutrition video series, our expanding Gastric Cancer Registry, and other advocacy activities.

Please consider making a donation today.

 
 

Thanks to Our National Sustaining Sponsors:

 

 

SHARE